Persistent Infection Drives the Development of CD8+ T Cells Specific for Late Lytic Infection Antigens in Lymphocryptovirus-infected Macaques and Epstein-Barr Virus-infected Humans

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2011 Sep 16

PMID 21917961

Citations 7

Authors

Nina Orlova

Fred Wang

Mark H Fogg

Affiliations

Soon will be listed here.

Abstract

We examined the CD8(+) T cell repertoire against lytic infection antigens in rhesus macaques persistently infected with the Epstein-Barr virus (EBV)-related lymphocryptovirus (rhLCV). CD8(+) T cells specific for late (L) antigens were detected at rates comparable to those for early antigens and were associated with increasing duration of infection. L antigen-specific CD8(+) T cells were also readily detected in adult, EBV-positive humans. Thus, viral major histocompatibility complex class I (MHCI) immune evasion genes expressed during lytic LCV infection do not prevent L-specific CD8(+) T cell development over time during persistent infection.

Citing Articles

Co-Infection of the Epstein-Barr Virus and the Kaposi Sarcoma-Associated Herpesvirus.

Boni M, Rieble L, Munz C Viruses. 2022; 14(12).

PMID: 36560713 PMC: 9782805. DOI: 10.3390/v14122709.

Proteome-wide analysis of CD8+ T cell responses to EBV reveals differences between primary and persistent infection.

Forrest C, Hislop A, Rickinson A, Zuo J PLoS Pathog. 2018; 14(9):e1007110.

PMID: 30248160 PMC: 6171963. DOI: 10.1371/journal.ppat.1007110.

Epstein-Barr Virus gp350 Can Functionally Replace the Rhesus Lymphocryptovirus Major Membrane Glycoprotein and Does Not Restrict Infection of Rhesus Macaques.

Herrman M, Muhe J, Quink C, Wang F J Virol. 2015; 90(3):1222-30.

PMID: 26559839 PMC: 4719629. DOI: 10.1128/JVI.02531-15.

Identification and functional comparison of seven-transmembrane G-protein-coupled BILF1 receptors in recently discovered nonhuman primate lymphocryptoviruses.

Spiess K, Fares S, Sparre-Ulrich A, Hilgenberg E, Jarvis M, Ehlers B J Virol. 2014; 89(4):2253-67.

PMID: 25505061 PMC: 4338891. DOI: 10.1128/JVI.02716-14.

CD8+ T cell responses to lytic EBV infection: late antigen specificities as subdominant components of the total response.

Abbott R, Quinn L, Leese A, Scholes H, Pachnio A, Rickinson A J Immunol. 2013; 191(11):5398-409.

PMID: 24146041 PMC: 5580796. DOI: 10.4049/jimmunol.1301629.

References

Hansen S, Powers C, Richards R, Ventura A, Ford J, Siess D . Evasion of CD8+ T cells is critical for superinfection by cytomegalovirus. Science. 2010; 328(5974):102-6. PMC: 2883175. DOI: 10.1126/science.1185350. View

Fogg M, Kaur A, Cho Y, Wang F . The CD8+ T-cell response to an Epstein-Barr virus-related gammaherpesvirus infecting rhesus macaques provides evidence for immune evasion by the EBNA-1 homologue. J Virol. 2005; 79(20):12681-91. PMC: 1235856. DOI: 10.1128/JVI.79.20.12681-12691.2005. View

Yao Q, Tierney R, Croom-Carter D, Dukers D, Cooper G, Ellis C . Frequency of multiple Epstein-Barr virus infections in T-cell-immunocompromised individuals. J Virol. 1996; 70(8):4884-94. PMC: 190438. DOI: 10.1128/JVI.70.8.4884-4894.1996. View

Catalina M, Sullivan J, Bak K, Luzuriaga K . Differential evolution and stability of epitope-specific CD8(+) T cell responses in EBV infection. J Immunol. 2001; 167(8):4450-7. DOI: 10.4049/jimmunol.167.8.4450. View

Fogg M, Garry D, Awad A, Wang F, Kaur A . The BZLF1 homolog of an Epstein-Barr-related gamma-herpesvirus is a frequent target of the CTL response in persistently infected rhesus macaques. J Immunol. 2006; 176(6):3391-401. DOI: 10.4049/jimmunol.176.6.3391. View

Tierney R, Edwards R, Sitki-Green D, Croom-Carter D, Roy S, Yao Q . Multiple Epstein-Barr virus strains in patients with infectious mononucleosis: comparison of ex vivo samples with in vitro isolates by use of heteroduplex tracking assays. J Infect Dis. 2005; 193(2):287-97. DOI: 10.1086/498913. View

van Gent M, Griffin B, Berkhoff E, van Leeuwen D, Boer I, Buisson M . EBV lytic-phase protein BGLF5 contributes to TLR9 downregulation during productive infection. J Immunol. 2010; 186(3):1694-702. DOI: 10.4049/jimmunol.0903120. View

Rabin H, Neubauer R, Hopkins 3rd R, Nonoyama M . Further characterization of a herpesvirus-positive orang-utan cell line and comparative aspects of in vitro transformation with lymphotropic old world primate herpesviruses. Int J Cancer. 1978; 21(6):762-7. DOI: 10.1002/ijc.2910210614. View

Apolloni A, Sculley T . Detection of A-type and B-type Epstein-Barr virus in throat washings and lymphocytes. Virology. 1994; 202(2):978-81. DOI: 10.1006/viro.1994.1422. View

10.

Rooney C, Smith C, Ng C, Loftin S, Li C, Krance R . Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet. 1995; 345(8941):9-13. DOI: 10.1016/s0140-6736(95)91150-2. View

11.

Hislop A, Ressing M, van Leeuwen D, Pudney V, Horst D, Koppers-Lalic D . A CD8+ T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med. 2007; 204(8):1863-73. PMC: 2118677. DOI: 10.1084/jem.20070256. View

12.

Rivailler P, Jiang H, Cho Y, Quink C, Wang F . Complete nucleotide sequence of the rhesus lymphocryptovirus: genetic validation for an Epstein-Barr virus animal model. J Virol. 2001; 76(1):421-6. PMC: 135707. DOI: 10.1128/jvi.76.1.421-426.2002. View

13.

Fogg M, Wirth L, Posner M, Wang F . Decreased EBNA-1-specific CD8+ T cells in patients with Epstein-Barr virus-associated nasopharyngeal carcinoma. Proc Natl Acad Sci U S A. 2009; 106(9):3318-23. PMC: 2651339. DOI: 10.1073/pnas.0813320106. View

14.

Sculley T, Apolloni A, Hurren L, Moss D, Cooper D . Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects. J Infect Dis. 1990; 162(3):643-8. DOI: 10.1093/infdis/162.3.642. View

15.

Pudney V, Leese A, Rickinson A, Hislop A . CD8+ immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med. 2005; 201(3):349-60. PMC: 2213038. DOI: 10.1084/jem.20041542. View

16.

Croft N, Shannon-Lowe C, Bell A, Horst D, Kremmer E, Ressing M . Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle. PLoS Pathog. 2009; 5(6):e1000490. PMC: 2695766. DOI: 10.1371/journal.ppat.1000490. View

17.

Zuo J, Currin A, Griffin B, Shannon-Lowe C, Thomas W, Ressing M . The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009; 5(1):e1000255. PMC: 2603334. DOI: 10.1371/journal.ppat.1000255. View

18.

Zuo J, Thomas W, van Leeuwen D, Middeldorp J, Wiertz E, Ressing M . The DNase of gammaherpesviruses impairs recognition by virus-specific CD8+ T cells through an additional host shutoff function. J Virol. 2007; 82(5):2385-93. PMC: 2258936. DOI: 10.1128/JVI.01946-07. View

19.

Horst D, van Leeuwen D, Croft N, Garstka M, Hislop A, Kremmer E . Specific targeting of the EBV lytic phase protein BNLF2a to the transporter associated with antigen processing results in impairment of HLA class I-restricted antigen presentation. J Immunol. 2009; 182(4):2313-24. DOI: 10.4049/jimmunol.0803218. View

20.

Cho Y, Gordadze A, Ling P, Wang F . Evolution of two types of rhesus lymphocryptovirus similar to type 1 and type 2 Epstein-Barr virus. J Virol. 1999; 73(11):9206-12. PMC: 112954. DOI: 10.1128/JVI.73.11.9206-9212.1999. View